433 related articles for article (PubMed ID: 11042560)
1. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
2. Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer.
Shimada H; Nabeya Y; Okazumi S; Matsubara H; Kadomatsu K; Muramatsu T; Ikematsu S; Sakuma S; Ochiai T
Oncol Rep; 2003; 10(2):411-4. PubMed ID: 12579281
[TBL] [Abstract][Full Text] [Related]
3. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
4. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
Dong J; Zeng BH; Xu LH; Wang JY; Li MZ; Zeng MS; Liu WL
J Transl Med; 2010 Sep; 8():81. PubMed ID: 20813067
[TBL] [Abstract][Full Text] [Related]
5. [The value of serum tumor marker in the diagnosis of lung cancer].
Shi GL; Hu XL; Yue SD; Song CX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
[TBL] [Abstract][Full Text] [Related]
6. [Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer].
Mao YS; Zhang DC; Zhao XH; Wang LJ; Qi J; Li XX
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):457-60. PubMed ID: 14575569
[TBL] [Abstract][Full Text] [Related]
7. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma.
Shimada H; Nabeya Y; Okazumi S; Matsubara H; Shiratori T; Gunji Y; Kobayashi S; Hayashi H; Ochiai T
Surgery; 2003 May; 133(5):486-94. PubMed ID: 12773976
[TBL] [Abstract][Full Text] [Related]
8. Detection of serum p53 antibodies in mucosal esophageal cancer and negative conversion after treatment.
Shimada H; Arima M; Nakajima K; Koide Y; Okazumi S; Matsubara H; Miyazawa Y; Takeda A; Hayashi H; Yoshida T; Ochiai T; Isono K
Am J Gastroenterol; 1998 Aug; 93(8):1388-9. PubMed ID: 9707082
[No Abstract] [Full Text] [Related]
9. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.
Yamamoto K; Oka M; Hayashi H; Tangoku A; Gondo T; Suzuki T
Cancer; 1997 May; 79(9):1647-55. PubMed ID: 9128978
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma.
Kuboshima M; Shimada H; Liu TL; Nakashima K; Nomura F; Takiguchi M; Hiwasa T; Ochiai T
Int J Oncol; 2006 Feb; 28(2):463-8. PubMed ID: 16391802
[TBL] [Abstract][Full Text] [Related]
12. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.
Yi Y; Li B; Wang Z; Sun H; Gong H; Zhang Z
Biomarkers; 2009 Nov; 14(7):480-5. PubMed ID: 19863186
[TBL] [Abstract][Full Text] [Related]
13. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
14. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
15. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
[TBL] [Abstract][Full Text] [Related]
16. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer.
Brockmann JG; St Nottberg H; Glodny B; Sprakel B; Senninger N
Anticancer Res; 2000; 20(6D):4899-904. PubMed ID: 11332443
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and fundamental study of a squamous cell carcinoma related antigen (SCC-RA) for esophageal squamous cell carcinoma].
Ikeda K
Nihon Geka Gakkai Zasshi; 1991 Apr; 92(4):387-96. PubMed ID: 1870566
[TBL] [Abstract][Full Text] [Related]
18. Serum anti-p53 antibodies as a diagnostic tumor marker: observations in patients with malignant and premalignant oral cavity lesions.
Porrini R; Vercellino V; Rocchetti V; Renò F; Giorda E; Pomato E; Cannas M; Sabbatini M
Minerva Stomatol; 2010 May; 59(5):233-9, 239-43. PubMed ID: 20502428
[TBL] [Abstract][Full Text] [Related]
19. Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathologic features and tumor markers.
Shimada H; Nakajima K; Ochiai T; Koide Y; Okazumi SI; Matsubara H; Takeda A; Miyazawa Y; Arima M; Isono K
Oncol Rep; 1998; 5(4):871-4. PubMed ID: 9625835
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of serum levels of SCC antigen in patients with esophageal squamous cell carcinoma].
Ikeda K; Terashima M; Ishida K; Okamoto K; Suzuki S; Murakami K; Ohtsu T; Suzuki K; Niitsu Y; Obonai H
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):677-82. PubMed ID: 3355186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
